Genaissance Pharmaceuticals, Inc. is developing innovative products based on its proprietary pharmacogenomic technology and has a revenue-generating business in DNA and pharmacogenomic products and services. Genaissance also markets its proprietary FAMILION(TM) Test, designed to detect mutations responsible for causing Familial Long QT and Brugada Syndromes, two causes of sudden cardiac death. The Company's product development strategy is focused on drug candidates with promising clinical profiles and finding genetic markers to identify a responsive patient population. This strategy enables Genaissance to leverage existing clinical data and, thus, reduce the costs and risks associated with traditional drug development and increase the probability of clinical success and commercialization. The Company's lead therapeutic product, vilazodone for depression, is in Phase II of development.
View Top Employees from Genaissance Pharmaceuticals , Inc.Website | http://www.genaissance.com |
Revenue | $20 million |
Employees | View employees |
Founded | 1992 |
Address | 5 Science Park, New Haven, Connecticut 06511, US |
Phone | (203) 773-1450 |
Fax | (203) 562-9377 |
Industry | Manufacturing General, Biotechnology, Manufacturing, Other Healthcare Services |
Competitors | Assurex Health, Crystax Pharmaceuticals / Oryzon Genomics, GPC Biotech AG, Strand Life Sciences, deCODE genetics |
SIC | SIC Code 87 Companies, SIC Code 873 Companies |
NAICS | NAICS Code 54171 Companies, NAICS Code 541710 Companies, NAICS Code 54 Companies, NAICS Code 5417 Companies, NAICS Code 541711 Companies, NAICS Code 541 Companies |
Looking for a particular Genaissance Pharmaceuticals , Inc. employee's phone or email?
The Genaissance Pharmaceuticals , Inc. annual revenue was $20 million in 2024.
Genaissance Pharmaceuticals , Inc. is based in New Haven, Connecticut.
The NAICS codes for Genaissance Pharmaceuticals , Inc. are [54171, 541710, 54, 5417, 541711, 541].
The SIC codes for Genaissance Pharmaceuticals , Inc. are [87, 873].